The home of Phase 1 in oncology
In light of the high number of COVID-19 cases and concerns about the new SARS-CoV-2 variant, ESMO has made the decision to hold the ESMO Targeted Anticancer Therapies Congress 2022 as a virtual event only, with no in-person participation in Paris.
The safety of our faculty and delegates remains our top priority at this difficult time.
We are confident that our virtual format will effectively disseminate the latest advances in phase I oncology trials and give experts from all around the world the chance to identify promising new research avenues.
ESMO TAT 2022, known as “The Home of Phase I in Oncology” will offer participants a glimpse of the future of targeted anticancer therapies, focusing on promising new anticancer targets and agents, with a particular focus on those in early phase clinical development.
Stakeholders from academia and industry will discuss with clinicians, researchers, and regulators the global dissemination of knowledge and clinical research expertise in the field of innovative cancer therapeutics, to the benefit of cancer patients worldwide.
- Ruth Plummer, Newcastle-upon-Tyne, UK
- Lillian Siu, Toronto, ON, Canada
ESMO Head Office
Via Ginevra 4, 6900 Lugano